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ApoptosisAlthough epigenetic drugs have been approved for use in selected malignancies, there is signiﬁcant need for a
better understanding of their mechanism of action. Here, we study the action of a clinically approved
DNA-methyltransferase inhibitor – decitabine (DAC) – in acute myeloid leukemia (AML) cells. At low
doses, DAC treatment induced apoptosis of NB4 Acute Promyelocytic Leukemia (APL) cells, which was asso-
ciated with the activation of the extrinsic apoptotic pathway. Expression studies of the members of the Death
Receptor family demonstrated that DAC induces the expression of TNF-related apoptosis-inducing ligand
(TRAIL). Upregulation of TRAIL, upon DAC treatment, was associated with speciﬁc epigenetic modiﬁcations
induced by DAC in the proximity of the TRAIL promoter, as demonstrated by DNA demethylation, increased
DNaseI sensitivity and histone acetylation of a non-CpG island, CpG-rich region located 2 kb upstream to the
transcription start site. Luciferase assay experiments showed that this region behave as a DNA methylation
sensitive transcriptional regulatory element. The CpG regulatory element was also found methylated in sam-
ples derived from APL patients. These ﬁndings have been conﬁrmed in the non-APL, AML Kasumi cell line,
suggesting that this regulatory mechanism may be extended to other AMLs. Our study suggests that DNA
methylation is a regulatory mechanism relevant for silencing of the TRAIL apoptotic pathway in leukemic
cells, and further elucidates the mechanism by which epigenetic drugs mediate their anti-leukemic effects.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
DNA methylation of cytosine residues by DNA-methyltransferases
(DNMTs) is an important epigenetic modiﬁcation which, in conjunc-
tion with histone post-translational modiﬁcations, imposes distinct
chromatin structures that regulate gene expression [1]. In general,
transcriptionally active regions are associated with histone acetyla-
tion and DNA demethylation, while transcriptionally inactive regions
are associated with histone deacetylation and DNA methylation [1,2].r Decitabine; DNMT, DNA
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rights reserved.DNA hypermethylation, through the recruitment of methyl-DNA
binding proteins and the engagement of histone modifying enzymes,
is able to induce chromatin condensation which represents an
impediment to active gene transcription [3–5]. Although initially
studied in CpG-rich, promoter associated, CpG islands, DNA methyla-
tion is being increasingly recognized as a potential transcriptional
regulatory mechanism also in non-CpG island regions [6].
Importantly, chromatin alterations within the DNA regulatory
regions of both oncogenes and oncosuppressors have been found in
several cancer types [7,8]. Acute Promyelocytic Leukemia (APL) is a
subtype of acute myeloid leukemias, and represents a paradigm for
cell transformation caused by the establishment of an aberrant epige-
netic status leading to gene silencing [9]. The balanced chromosomal
translocation t(15;17) promotes the generation of the oncogenic
PML–RAR fusion protein which behaves as an altered transcription
factor – wild-type RARα – recruiting different chromatin modifying
enzymes (as histone-deacetylases – HDACs – and DNMTs) and
inducing stable silencing of RARα target genes at physiological
concentrations of retinoic acid [10–12]. These transcriptional changes
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genetic lesions leads to the development of leukemia.
The re-establishment in cancer cells of a normal chromatin status
by using inhibitors of chromatin modifying enzymes is the goal
of “epigenetic therapy” [13–18]. DAC (Decitabine or 5-aza-2′-
deoxycytidine) is a prototypical member of the DNMT-inhibitor
(DNMTi) family of nucleoside analogs. This inhibitor is incorporated
into DNA during cell replication and, through covalent binding to
DNMTs, blocks their enzymatic activity [19]. At low concentrations,
DAC is able to induce selectively DNA hypomethylation [13,20–22].
DNMTi – alone or together with HDAC inhibitors (HDACi) – has
been shown to re-induce silenced cancer suppressor genes in tumor
cells [23]. Clinical trials on AML patients, using different epigenetic
drugs, showed an improved survival rate associated with low toxicity
[14,24] but the mechanism of action of these drugs remains poorly
understood. This lack of knowledge limits the optimal use of epige-
netic therapies, and is reﬂected by the lack of validated biomarkers
to monitor the efﬁcacy of treatment [25].
In the present work, we studied the effects of DAC treatment in a
human APL cell line expressing PML–RAR (NB4 cells) and in a human
AML cell line expressing AML1-ETO (Kasumi cells), showing that
silencing of TRAIL through epigenetic mechanisms represents part
of the anti-apoptotic defenses of cancer cells, that can be reverted
by epigenetic therapy.
2. Materials and methods
2.1. Cell lines
NB4 and Kasumi cell lines were cultured in RPMI medium
containing 10% Fetal Bovine Serum, 2 mM glutamine and antibiotics.
DAC (Sigma-Aldrich, St. Louis, MO) was dissolved in PBS and admin-
istered at the described doses. In some experiments (Fig. 3B–D), we
used NB4-Bcl2 cells that have been derived from NB4 cells uponC D
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Fig. 1. DAC activates the extrinsic pathway of apoptosis. (A) Western blot analysis of PML–R
left untreated (NT) for 3 days. (B) Immunoﬂuorescence staining of the indicated cells with
NB4 cells treated with increasing doses of DAC for 3 days, measuring TdT positivity. (*) ind
analysis measuring TdT positivity of NB4 cells treated with 0.5 μM of DAC for the indicate
immunoblot against cleaved caspases 8 and 9. Note that caspase 9 is already partially activtransfection of a Bcl2 expression vector. The use of NB4-Bcl2 cells –
that are more resistant to DAC-induced apoptosis (Fig. S1) – led to
the recovery of a higher number of cells following DAC treatment
for mechanistical studies, since original NB4 cells treated with DAC
show TRAIL associated induction of apoptosis (see Fig. 1).
2.2. RNA analysis
RNA from BM and spleen cells was puriﬁed using RNeasy Mini Kit
(Qiagen, Valencia, CA), quantiﬁed, reverse transcribed, and the
cDNA was used to perform quantitative PCR (qPCR) using SYBR
Green Reaction Mix (Perkin Elmer, Boston, MA) and TRAIL speciﬁc
primers: fwd 5′-CCAGAGGAAGAAGCAACACATTG-3′; rev 5′-GCC
CACTCCTTGATGATTCCC-3′.
2.3. Flow cytometry
Apoptosis quantiﬁcation of cell lines was determined by TUNEL
staining (In Situ Cell Death Detection Kit, Fluorescein-Roche Applied
Science) according to themanufacturer's instructions. TRAIL expression
in NB4 cells was detected with anti human TRAIL mAb (R&D systems
Minneapolis, MN). For all studies we used FACSCantoII, and FACSDiva
Software (BD Bioscience, San Jose, CA).
2.4. Western blot analysis
Whole cell extracts from splenocytes were separated by SDS-
PAGE. Antibodies against cleaved Caspases 8 and 9 (Cell Signaling
Technology, Danvers, MA) were used to reveal the target proteins.
2.5. DNA methylation assay
DNAmethylation wasmeasured by bisulﬁte genomic sequencing as
described [26]. Ampliﬁcation of bisulﬁte-modiﬁed DNA for promoterE
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available upon request.
2.6. qPCR-based DNaseI assays and Chromatin immunoprecipitation
(ChIP)
NB4 or Kasumi cells were treated with 0.5 μM DAC daily for
3 days. To avoid apoptosis-associated histone deacetylation [28], we
performed a Ficoll separation before adding formaldehyde for 5 min
(1% ﬁnal concentration). qPCR-based DNaseI assays of CpG-A was
carried out as described [29,30]. ChIP was performed as described
by Di Croce et al. [10]. The antibodies used for ChIP assay were the fol-
lowing: anti-H3 (ab1791, AbCam, Cambridge, UK); anti-panAcetylH3
(06–599, Millipore, Billerica, MA). Primer sequences used for ChIP:
CpG-A: fwd 5′ ATGATGTACGTGAAAGGCATGAA 3′ rev 5′ ACTTCCTGC
ACGTTTCCCAT 3′; ATrich: fwd 5′ ACTAGCATGGATCTGCTGACT G 3′
rev 5′ ACTTGAACCCAGGAGGTGGAGG 3′. Primer sequences used for
qPCR-based DNaseI assays: CpG-A: fwd 5′ ATTTGAGGAGTTACAAGA
GTCGGCT 3′ rev 5′ CCACCACCATGCCCTAATAATTT 3′.
2.7. Luciferase reporter vector generation
The human TRAIL promoter (nucleotides−46/−2531 from TSS)
and the CpG-A regulatory element (nucleotides −2010/−2361
from TSS) were PCR ampliﬁed from genomic DNA, using the
listed primers: full length TRAIL fwd 5′ CTTAGATCGCAGATCTCT
TAGATCGCAGATCTACTGAAGCCC TTCCTTCTCTATTC 3′ rev 5′ CCGAG
CTCTTACGCGTCCGAGCTCTTACGCGTGCTCAAAGAT AGAGGTAGCCAGAC
3′; CpG-A fwd 5′ TGCAGATCGCAGATCTTGCAGATCGCAGATCT GCACG
TAAGAAAGTCTAGAGTGTGG 3′ rev 5′ CCGAGCTCTTACGCGTCCGAGCTCT
TACGC GTGCTCAAAGATAGAGGTAGCCAGAC 3′. The PCR products were
cloned respectively into the pGL3 and pGL3-promoter vectors as
MluI-BglII fragments using In-Fusion PCR cloning kit (Clontech Laborato-
ries, Inc. CA, USA).
2.8. In vitro methylation and luciferase assay
Reporter plasmids containing the full hTRAIL promoter or the
CpG-A regulatory region were in vitro methylated by incubation
with M. SsI CpG methylase enzyme (New England Biolabs, Ipswich,
MA). Transient transfections of Phoenix cells were performed using
the calcium-phosphate method. Brieﬂy, the un-methylated or in
vitro methylated plasmid (5 μg) carrying the full hTRAIL promoter
or the regulatory element was co-transfected with 2.5 μg of
CMV-β-Galactosidase plasmid. After 24 h, cells were lysed in passive
lysis buffer (Promega Fitchburg, WI). Cellular lysates were used
to measure luciferase activity using a luminometer (Victor III,
Perkin-Elmer/Wallace, Akron, OH). Transfection efﬁciency was nor-
malized against β-galactosidase activity.
2.9. Immunoﬂuorescence
NB4 cells, treatedwith ATRA, DAC or left untreated,were transferred
by cytospin to histological glasses and ﬁxedwith 4% paraformaldehyde,
permeabilized with 0.1% Triton-X and blocked with 5% normal goat
serum. Staining was performed using a mouse anti human PML anti-
body (PGM3) [10] to reveal PML-Nuclear Bodies or microspeckles.
A Cy3-conjugated goat anti-mouse (Jackson ImmunoResearch Labora-
tories, Inc., West Grove, PA, USA) was used as secondary antibody.
2.10. Statistical analysis
All data have been analyzed with a Student's t test, if not differently
speciﬁed, and were considered signiﬁcant for α=0.05.3. Results
3.1. DAC treatment does not act directly on the PML–RAR protein
To study DAC in APL, we made use of a human cell line (NB4)
established from an APL patient that expresses the PML–RAR
oncoprotein [31]. First, we veriﬁed whether DAC has any effect on
PML–RAR levels, since in human APL cells, both All-Trans Retinoic
Acid (ATRA) and the well known HDAC inhibitor Valproic Acid are
able to induce PML–RAR degradation [9,32,33]. In contrast, DAC did
not induce PML–RAR degradation in NB4 cells (Fig. 1A). PML–RAR
alters the morphology of the wild-type PML-associated nuclear
bodies, inducing a nuclear microspeckled pattern that can be reverted
by ATRA [9]. Consistent with the western blot studies, we observed
that PML–RAR induced microspeckles are not altered by DAC treat-
ment of NB4 cells (Fig. 1B). Taken together, these results indicate
that DAC does not act directly on PML–RAR levels and localization.
3.2. DAC induces apoptosis in human APL cells, associated with activation
of the extrinsic pathway
We then veriﬁed the effect of increasing doses of DAC on NB4 cells.
Indeed, DAC induced apoptosis in a dose-dependent manner up to a
concentration of 0.5 μM, (Fig. 1C). DAC at 0.5 μM induces DNA
hypomethylation at the PML–RAR target RARß2 promoter [10]. We
therefore used this dose to perform a time course on NB4 cells: a
signiﬁcant induction of apoptosis was observed only after 3 days of
treatment (Fig. 1D). The delayed effect of DAC is consistent with its
mechanism of action, and the need for the drug to integrate in DNA
and bind DNMTs during at least two cell cycles to inhibit DNA
methylation [17].
To further elucidate which functional apoptotic pathway was acti-
vated by DAC, we veriﬁed the cleavage of caspase 8 and 9, two down-
stream events that have been shown to occur upon speciﬁc activation
of the Death Receptors (or extrinsic) pathway or of the Intrinsic path-
way, respectively [34–37]. Upon three days of treatment with DAC,
NB4 cells showed an increased cleavage of Caspase 8 compared to
control cells, while Caspase 9 was not affected by DAC treatment
(Fig. 1E), demonstrating that the extrinsic pathway is selectively
induced during DAC-dependent apoptosis.
3.3. DAC induces TRAIL expression
Induction of apoptosis has been shown to play an important role
in the anti-leukemic effect of HDAC inhibitors in NB4 cells, due to
the activation of the TRAIL pathway [15,38]. We measured the
mRNA levels for several members of the Death Receptor pathway
following DAC treatment: while none of the studied receptors
showed a signiﬁcant increase of mRNA expression, we observed
that DAC induced mRNA expression of the TRAIL ligand (Fig. 2A and
data not shown). Consistently, we observed an increased fraction of
NB4 cells expressing TRAIL by FACS analysis following DAC treatment,
in the absence of FAS-L induction (Fig. 2B and data not shown).
3.4. DAC promotes DNA hypomethylation and an open chromatin conﬁg-
uration of a CpG rich region upstream of the TRAIL promoter
To investigate more in details the mechanism of DAC-mediated
induction of TRAIL, we performed an in silico study examining
approximately 3 kb upstream of the human TRAIL transcription
start site (TSS), to identify CpG rich regions which could be affected
by DAC. Two CpG-rich regions, approximately 150 bp long (CpG-A
and CpG-B), were identiﬁed (Fig. 3A). Bisulﬁte sequencing assays,
performed to analyze the status of DNA methylation in these regions,
revealed that CpG-A was almost completely methylated in NB4 cells
(Fig. 3B, upper panel), while CpG-B was completely unmethylated
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Fig. 2. DAC treatment induces TRAIL expression in NB4 cells. (A) TRAIL mRNA fold
induction in NB4 cells treated with 0.5 μM DAC for 2 days vs untreated (NT). (B) Cell
surface expression of TRAIL measured by FACS in NB4 cells treated with 0.5 μM DAC
or left untreated (NT).
117M. Soncini et al. / Biochimica et Biophysica Acta 1832 (2013) 114–120(data not shown). We therefore decided to analyze the DNA methyl-
ation status of CpG-A in DAC treated NB4 cells. DAC treatment led to a
signiﬁcant DNA hypomethylation of the CpG-A region, ranging from
20 to 50%, depending on the CpG dinucleotides taken into consider-
ation (Fig. 3B, lower panel). Importantly, changes in DNAmethylation
were accompanied by concomitant changes in the associated chro-
matin as shown by a signiﬁcant increase in the levels of histone H3
acetylation in close proximity to the CpG-A region, but not in an
AT-rich region that is lying approximately 500 bp apart (Fig. 3C).0%
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DNaseI sensitivity assays to measure the accessibility of the CpG-A element in NB4 cells t
in accessibility in DAC-treated cells after DNAseI digestion of isolated nuclei, as a decreasUpon DAC treatment, CpG-A showed an increased sensitivity to
DNaseI treatment compared to untreated cells (Fig. 3D), linking the
increased histone H3 acetylation to a more accessible chromatin
conﬁguration. Thus, DAC induces chromatin changes in the proximity
of TRAIL promoter region, associated with its induction.3.5. The CpG-A region is a DNA regulatory module, and its activity is
affected by DNA methylation
To further investigate the importance of DNA methylation of
the CpG-A region in regulating TRAIL expression, and to directly
validate this region as a transcriptional regulatory element, we used
a standard luciferase gene-reporter approach [10,39]. First of all, the
full TRAIL promoter, including the CpG-A region, was cloned
upstream of the Luc reporter gene (Fig. 4A). After in vitro methyla-
tion, the TRAILp-LUC plasmid was used in the luciferase reporter
assay: DNA methylation decreased the reporter gene activity,
suggesting that DNA methylation may indeed regulate its activity
(Fig. 4B). We wanted then to deﬁne more precisely the role of the
CpG-A region, so we cloned a DNA fragment spanning the CpG-A
region upstream of the SV40 minimal promoter in a Luc reporter
plasmid (Fig. 4A). The CpG-A-LUC plasmid was tested in luciferase
reporter assays, and we observed that the CpG-A region increased
the basal promoter activity, indicating an active regulatory role
(Fig. 4C). Following in vitro methylation, the CpG-A-LUC plasmid
showed a strong decrease of the reporter gene activity (Fig. 4D),
supporting a model where the activity of CpG-A is regulated by its
DNA methylation status.iCpG CpG-B
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Taken together, our data suggest that DNA hypomethylation of the
CpG-A region could play an important role in the induction of TRAIL
by DAC. To verify whether the data obtained in NB4 cells may be of
potential clinical relevance, we tested the levels of DNA methylation
of the CpG-A region in four APL patient samples. Strikingly, we
found that in all the tested samples the CpG-A was highly methylated
(Fig. 5), consistent with the lack of expression of TRAIL in APL
samples and supporting a mechanism of DNA methylation mediated
silencing [15,38].
3.7. DAC activates the apoptotic extrinsic pathway in Kasumi cells
To investigate whether the observed mechanism could be extended
to non-APLmyeloid leukemias, we used the Kasumi cell line expressingPatient 1 (04/673)
CpGs
1 10987652 3 4
C
Patient 3 (02/130)
Fig. 5. CpG-A region is hypermethylated in APL patient blasts. Bisulphite sequencing hAML1/ETO. Treatment of Kasumi cells with DAC induced both apoptosis
and TRAIL expression (Fig. 6A and B). TRAIL induction was associated
with selective cleavage of caspase 8 (Fig. 6C), suggesting that themech-
anism involved in DAC anti-leukemic activity is functional also in
non-APL leukemic cells. Bisulﬁte analysis demonstrated that the
CpG-A region is methylated in Kasumi cells, and that DAC induces its
demethylation (Fig. 6D), further supporting the hypothesis of a direct
role of DNA methylation of this region in TRAIL silencing in AMLs.
4. Discussion
Our work has led to the identiﬁcation of a regulatory region,
upstream of the TRAIL promoter, hypermethylated in AML cell lines
and in human APL samples. DAC treatment induces hypomethylation
of this region which is accompanied by the induction of the TRAIL
promoter and activation of the apoptotic extrinsic pathway.Patient 2 (06/1820)
pGs
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as been performed on blasts derived from peripheral blood of four APL patients.
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Fig. 6. DAC induces TRAIL expression, apoptosis and DNA demethylation of the CpG-A element in Kasumi AML cells. Time course analysis of Kasumi cells treated daily with 0.5 μM
DAC. FACS analysis was performed to detect TdT (apoptosis) (A) and TRAIL expression (B). (**) indicates signiﬁcant differences at Tukey's multiple comparison test (α≤0.01).
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epigenetic events: both HDAC inhibitors and DNA demethylating
agents are able to induce reactivation of the gene, though the two
mechanisms of induction do not appear to be totally overlapping. In
fact, DAC induces DNA demethylation of the CpG-A region and a
concomitant increase in histone acetylation, supporting the concept
of interdependent processes [40]. In contrast, treatment with HDAC
inhibitors (such as VPA) speciﬁcally enhances histone acetylation,
while the CpG-A region remains methylated (our unpublished obser-
vations): the possibility of transcriptional induction in the presence of
DNAmethylation of a regulatory element is not unprecedented, and it
has been described in other dynamically regulated systems (for
example see [41]), and VPA may also work through induced histone
hyperacetylation at other regulatory regions. In any case, the CpG-A
region can be considered as a further example of a class of short
DNA elements regulated by DNA methylation, less well characterized
than the canonical CpG islands: these short CpG-containing elements
may represent an important layer of genome-wide regulation of
transcription through DNA methylation [6] and should be taken in
consideration when studying both gene regulation and responsive-
ness to epigenetic drugs.
Interestingly, we have failed to identify a direct role for PML–RAR
in epigenetic silencing of TRAIL: genome-wide studies (ChIP-Seq) of
its binding sites in NB4 cells are available, and there is no evidence
of a direct association of PML–RAR with the TRAIL promoter [11].
Consistent with the lack of a direct role for the fusion protein, DAC
did not induce PML–RAR degradation, that is a mechanism identiﬁed
for other agents – such as retinoic acid – targeting the fusion protein.
Integrating our results with previous reports, a general picture
emerges: (a) leukemic cells are intrinsically sensitive to TRAIL signaling
apoptosis [15,38,42]; (b) in AML cells, key components of the death
receptor pathway, in particular TRAIL, are transcriptionally silenced,
leading to increased cell survival; (c) epigenetic drugs (either HDACior DAC) can restore these pathways through gene reactivation, leading
to apoptosis [15,38,42]. From the data presented in this studywe cannot
exclude that other mechanisms in addition to TRAIL re-expression may
be relevant for the effect of DAC on leukemic cells. Gene expression
studies have shown that low doses of DACmay lead to alteration of sev-
eral cancer pathways, not necessarily acutely triggering apoptosis [22].
The apoptotic effect observed here upon DAC treatment, however, is
also observed at clinically relevant doses, and has been linked to induc-
tion of TRAIL and apoptosis: indeed, activation of caspase 8 and absence
of up-regulation of other members of the death receptor pathways
signaling supports the notion that TRAIL represents a key molecule in
mediating DAC induced apoptosis.
Our results are consistent with a recent report, showing epigenetic
silencing by DNA methylation of the TRAIL promoter occurring during
oncogene induced stepwise tumorigenesis [43]. Those studies showed
that a region that includes CpG-A may mediate silencing of the TRAIL
promoter in epithelial cells. Since our studies showed that indeed the
CpG-A region is endowed with regulatory ability in different AML cell
lines, and is altered in primary APL cells, we propose that DNAmethyl-
ation of the CpG-A region can be therefore considered as a candidate
biomarker for monitoring the effectiveness of treatment with DAC for
AML, and potentially other forms of cancer.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2012.10.001.
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